Dehydroepiandrosterone-sulfate inhibits pancreatic carcinoma cell proliferation in vitro and in vivo

Surgery

Volumn 121, Issue 4, 1997, Pages 392-397

  Melvin, W Scott ^a,b   Boros, Laszlo G ^a   Muscarella, Peter ^a   Brandes, James L ^a   Johnson, Jerome A ^a   Fisher, William E ^a   Schirmer, William J ^a   Ellison, E Christopher ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYL SULFOXIDE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; PRASTERONE SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; TUMOR VOLUME;

EID: 0031000078     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(97)90308-1     Document Type: Article

References (35)

1. Vande W, Lieberman S. The metabolism of dehydroisoandrosterone. In: Pincus G, Vollmer E, editors. Biological activity of steroids in relation to cancer. New York: Academic Press, Inc, 1960:93-110.
2. Carlstrom K, Brody S, Lunnel NO, Lagrelius A, Mollerstrom G, Pousette A, et al. Dehydroepiandrosterone sulphate and dehydroepiandrosterone in serum: differences related to age and sex. Maturitas 1988;10:297-306.
3. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone-sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984;59:551-5.
4. Boccuzzi G, Di Monaco M, Brignardello E, Leonardi L, Gatto V, Pizzini A, et al. Dehydroepiandrosterone antiestrogenic action through androgen receptor in MCF-7 human breast cancer cell line. Anticancer Res 1993;13:2267-72.
5. Schulz S, Nyce JW. Inhibition of protein isoprenylation and p21ras membrane association by dehydroepiandrosterone in human colonic adenocarcinoma cells in vitro. Cancer Res 1991; 51:6563-7.
6. Ratko TA, Detrisac CJ, Mehta RG, Kelloff GJ, Moon RC. Inhibition of rat mammary gland chemical carcinogenesis by dietary dehydroepiandrosterone or a fluorinated analogue of dehydroepiandrosterone. Cancer Res 1991;51:481-6.
7. Pashko LL, Lewbart ML, Schwartz AG. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-promoted skin tumor formation in mice by 16 alpha-fluoro-5-androsten-17-one and its reversal by deoxyribonucleosides. Carcinogenesis 1991;12:2189-92.
8. Moler C, Benito M, Lorenzo M. Glucose-6-phosphate dehydrogenase gene expression in fetal hepatocyte primary cultures under nonproliferative and proliferative conditions. Exp Cell Res 1994;210:26-32.
9. Jonas SK, Benedetto C, Flatman A, et al. Increased activity of 6-phosphogluconate dehydrogenase and glucose-6-phosphate dehydrogenase in purified cell suspension and single cells from the uterine cervix in cervical intraepithelial neoplasia. Br J Cancer 1992;66:185-91.
10. Geertrudia NJ, Ilse MC, Klazina SB, Dingemans, Kornelis JF. Experimentally induced colon cancer metastases in rat liver increase the proliferation rate and capacity for purine catabolism in liver cells. Histochemistry 1993;100:41-51.
11. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics 1994. CA Cancer J Clin 1994;44:7-26.
12. Bueno DeMesquita HB, Maisonnueve P, Moerman CJ, Walker AM. Aspects of medical history and exocrine carcinoma of the pancreas: a population-based case-control study in the Netherlands. Int J Cancer 1992;52:17-23.
13. Friedman GD, Van Den Eeden SK. Risk factors for pancreatic cancer: an exploratory study. Int J Epidemiol 1993;22:30-7.
14. Shibata A, Mack TM, Paganini-Hill A, Ross RK, Henderson BE. A prospective study of pancreatic cancer in the elderly. Int J Cancer 1994;58:46-9.
15. Chayen J, Bitensky L, Aves EK, Jones GRN, Silcox AA, Cunningham GJ. Histochemical demonstration of 6-phosphogluconate dehydrogenase in proliferating cells. Nature 1962;195:714-5.
16. Eskey CJ, Koretsky AP, Domach MM, Jain RK. Role of oxygen vs. glucose in energy metabolism in a mammary carcinoma perfused ex vivo: direct measurement by 31P NMR. Proc Natl Acad Sci U S A 1993;90:2646-50.
17. Raylman RR, Fisher SJ, Brown RS, Ethier SP, Wahl RL. Fluorine-18-fluorodeoxy-glucose-guided breast cancer surgery with a positron-sensitive probe: validation in preclinical studies. J Nucl Med 1995;36:1869-74.
18. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36:1811-7.
19. Bares R, Klever P, Hauptmann S, Hellwig D, Fass J, Cremerius U, et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994;192:79-86.
20. Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Greenwald P, et al. Strategy and planning for chemopreventive drug development: clinical development plans: Chemoprevention Branch and Agent Development Committee, National Cancer Institute. J Cell Biochem Suppl 1994;20:55-62.
21. Gordon GB, Shantz L, Talalay P. Modulation of growth, differentiation and carcinogenesis by deydroepiandrosterone. Adv Enzyme Regul 1987;26:355-82.
22. DeWard F, DeLaive JW, Baanders VH. On the bimodal age distribution of mammary carcinoma. Br J Cancer 1960;14:437-48.
23. Bulbrook RD, HaywardJL, Spicer CC, Thomas BS. Abnormal excretion of urinary steroids by women with early breast cancer. Lancet 1962;2:1238-40.
24. Bulbrook RD, HaywardJL, Spicer CC. Relation between urinary androgen and corticoid excretion and subsequent breast cancer. Lancet 1971;12:395-8.
25. Zumoff B, Levin J, Rosenfeld RS, Markham M, Strain GW, Fukushima DK. Abnormal 24-hr mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer. Cancer Res 1981; 41:3360-3.
26. Schwartz AG. Inhibition of spontaneous breast cancer formation in female C3H (Avy/a) mice by long-term treatment with dehydroepiandrosterone. Cancer Res 1979;39:1129-32.
27. Schwartz AG, Tannen RH. Inhibition of 7,12-dimethylbenz[a]anthracene- and urethan-induced lung tumor formation in A/J mice by long-term treatment with dehydroepiandrosterone. Carcinogenesis 1981;2:1335-7.
28. Pashko LL, Schwartz AG, Abou-Gharbia M, Swern D. Inhibition of DNA synthesis in mouse epidermis and breast epithelium by dehydroepiandrosterone and related steroids. Carcinogenesis 1981;2:717-21.
29. Schwartz AG, Fairman DK, Polansky M, Lewbart ML, Pashko LL. Inhibition of 7,12-dimethylbenz[a]anthracene-initiated and 12-O-tetradecanoylphorbol-13-acetate-promoted skin papilloma formation in mice by dehydroepiandrosterone and two synthetic analogs. Carcinogenesis 1989;10:1809-13.
30. Pashko LL, Hard GC, Rovito RJ, Williams JR, Sobel EL, Schwartz AG. Inhibition of 7,12-dimethylbenz (a) anthracene-induced skin papillomas and carcinomas by dehydroepiandrosterone and 3-beta-methylandrost-5-en-17-one in mice. Cancer Res 1985; 45:164-6.
31. Nyce JW, Magee PN, Hard GC, Schwartz AG. Inhibition of 1,2-dimethyl-hidrazine-induced tumorigenesis in BALB/c mice by dehydroepiandrosterone. Carcinogenesis 1984;5:57-62.
32. Moore MA, Thamavit W, Tsuda H, Sato K, Ichihara A, Ito N. Modifying influence of dehydroepiandrosterone on the development of dihydroxy-di-n-propylnitrosamine-initiated lesions in the thyroid, lung and liver of F344 rats. Carcinogenesis 1986; 7:311-6.
33. Moore MA, Thamavit W, Tsuda H, Ito N. The influence of subsequent dehydroepiandrosterone, diaminopropane, phenobarbital, butylated hydroxyanisole and butylated hydroxytoluene treatment on the development of preneoplastic and neoplastic lesions in the rat initiated with di-hydroxy-di-n-propyl nitrosamine. Cancer Lett 1986;30:153-60.
34. Schwartz AG, Pashko L, Whitcomb JM. Inhibition of tumor development by dehydroepiandrosterone and related steroids [review]. Toxicol Pathol 1986;14:357-62.
35. Dyner TS, Lang W, Geaga J, Golub A, Stites D, Winger E, et al. An open-label dose-escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV disease. J Acquir Immune Defic Synd 1993;6:459-65.